UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

Vicebio has secured $100mn in Series B funding to further develop its vaccines for multiple respiratory infections.

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...

The series B fundraising will support the clinical development of next-generation multivalent vaccines against respiratory ...

Vicebio Ltd ("Vicebio"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing led by TCGX with ...

British biotech Vicebio has secured $100 million in a series B funding round to advance its next-generation vaccines against ...

The company said it is “very confident in Arexvy, which has a best-in class profile, including the highest efficacy (94 per ...

Actinium reported data from the Phase III SIERRA trial of Iomab-B for relapsed or refractory acute myeloid leukaemia (r/r AML ...

The trial investigated the efficacy and safety of a once-daily 10-mg, 20-mg, and 50-mg dose of monlunabant vs. placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome.